B.Riley Downgrades Mirati Therapeutics (MRTX) to Neutral
Tweet
Share
E-mailGet Alerts MRTX Hot Sheet
Price: $58.70 --0%
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 4 | New: 5
Rating Summary:
8 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 4 | New: 5
Join SI Premium – FREE
B.Riley analyst Kalpit Patel downgraded Mirati Therapeutics (NASDAQ: MRTX) from Buy to Neutral with a price target of $60.00 (from $65.00).
For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.
Shares of Mirati Therapeutics closed at $60.20 yesterday.
You May Also Be Interested In
- Citi Downgrades Lend Lease Group (LLC:AU) (LLESY) to Neutral
- Berenberg Downgrades Segro PLC (SGRO:LN) (SEGXF) to Hold
- Citi Downgrades Northern Star Resources (NST:AU) (NESRF) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
